Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer

Chest

Volumn 135, Issue 6, 2009, Pages 1588-1595

  Rivera, M Patricia ^a   Detterbeck, Frank C ^b   Socinski, Mark A ^a   Moore, Dominic T ^a   Edelman, Martin J ^c   Jahan, Thierry M ^d   Ansari, Rafat H ^e   Luketich, James D ^f   Peng, Guangbin ^g   Monberg, Matthew ^g   Obasaju, Coleman K ^g   Gralla, Richard J ^h  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Michiana Hematology Oncology   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h North Shore Long Island Jewish Health System ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TOTAL LUNG CAPACITY;

EID: 66649094446     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-1430     Document Type: Article

References (35)

1. van Rens MT, de la Riviere AB, Elbers HR, et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117:374-379 (Pubitemid 30111585)
2. National Cancer Institute. Gefitinib in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer. Available at: http://www.cancer.gov/clinicaltrials/MCC-13922. Accessed May 7, 2009
3. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247-253 (Pubitemid 34032618)
4. Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan- Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365-1373
5. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7-14 (Pubitemid 29469711)
6. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1-6 (Pubitemid 29027851)
7. Choong NW, Vokes EE. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 2005; 7(suppl):S98-S104 (Pubitemid 43285572)
8. Gupta N, Ahmed I, Steinberg H, et al. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol 2002; 25:96-100 (Pubitemid 34131039)
9. Maas KW, van der Lee I, Bolt K, et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 2003; 41:345-351 (Pubitemid 36970189)
10. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease: part 1. Cytotoxic drugs. Am Rev Respir Dis 1986; 133:321-340
11. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31:1187-1203
12. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol 1992; 19:508-520
13. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6(suppl):7-13 (Pubitemid 26014890)
14. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996; 22:15-31 (Pubitemid 26155745)
15. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 1996; 32A:243-248 (Pubitemid 26090117)
16. Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8:525-529 (Pubitemid 127746483)
17. Treat J, Belani C, Edelman M, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology Trial (A1-99002L) [abstract]. Proc Am Soc Clin Oncol 2005; 23:7025
18. Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10:943-947 (Pubitemid 29424574)
19. Pavlakis N, Bell DR, Millward MJ, et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80:286-291 (Pubitemid 27282323)
20. Sauer-Heilborn A, Kath R, Schneider CP, et al. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125:637-640 (Pubitemid 29502345)
21. Dimopoulou I, Efstathiou E, Samakovli A, et al. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol 2004; 15:1250-1255 (Pubitemid 39199313)
22. Dimopoulou I, Galani H, Dafni U, et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94:452-458 (Pubitemid 34081376)
23. Kudrik FJ, Rivera MP, Molina PL, Maygarden S, et al. Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature. Clin Lung Cancer 2002; 4:52-56
24. Detterbeck F, Socinski M, Gralla R, et al. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small-cell lung cancer (NSCLC). J Thorac Oncol 2008; 3:37-45
25. Gralla RJ, Edelman MJ, Detterbeck FC, et al. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 2009; 17:307-313
26. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7:1748-1756 (Pubitemid 19272848)
27. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0; an improved reference for grading the acute effects of cancer treatment-impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47:13-47 (Pubitemid 30179675)
28. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique; 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198
29. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26:948-968 (Pubitemid 41632054)
30. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202-1218
31. Castro M, Veeder MH, Mailliard JA, et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996; 109:939-944 (Pubitemid 26113634)
32. Cottin V, Tebib J, Massonnet B, et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109:933-938 (Pubitemid 26113633)
33. Leo F, Solli P, Spaggiari L, et al. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004; 77: 260-265
34. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87:491-496
35. Atkins BZ, D'Amico TA. Controversial issues regarding the use of induction chemotherapy for lung cancer. Semin Thorac Cardiovasc Surg 2005; 17:191-194 (Pubitemid 41614075)